Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC

This study will test the effectiveness of two standard neoadjuvant chemotherapy regimens plus an investigational drug (ivonescimab) that has dual action as both immunotherapy and therapy targeting the tumor's blood supply. This investigational drug is called ivonescimab.

NCT Number	NCT07743632
Lead Sponsor	University of Kansas Medical Center
Conditions	Breast Cancer, Triple Negative Breast Cancer
Enrollment	110 participants
Start Date	2026-09
Primary Completion	2032-12 (estimated)
Study Completion	2033-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-04